IOL Chemicals & Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vsxxmdzmk2a7kmi1dv64vuxq.pdf

Key Takeaways


Margin & Profitability

Kushal Kumar Rana: "In the fourth quarter of '25, we have achieved 6% EBITDA margin from chemicals as compared to '24, 3%. So we are going forward to 10%. So hopefully in the current year, we will achieve more than 6%."

Ibuprofen: Volume, Cost & China Entry

Abhay Raj Singh: "we are the backward integrated facility and we command the backward chain also and we are considered as one of the best cost-efficient company for the Ibuprofen"

Non-Ibuprofen Diversification

Rakesh Mahajan: "No doubt our ibuprofen margins are presently more than all other non-Ibu segment. But all other non-Ibu segment products are also potential to have EBITDA margin equivalent or more than Ibuprofen also, but it may take some time or it may take more revenue from the regulatory market, which we are trying for exploring that market at the earliest."

Chemical Segment: Stabilization, Not Growth

Abhay Raj Singh: "our chemical business is an enabler of cost efficiency and supply reliability not an independent growth engine exposed to global demand cycle"

Capex, Capacity & Greenfield Expansion


Export Trajectory & Regulatory Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth10–15% from all products, mix of volume and priceFY26
EBITDA marginMore than 15%FY26
Chemical EBITDA marginMore than 6%, targeting ~10%FY26
Export revenue shareScale to 40–45%Next 2 years
Peak revenue from existing capacityINR2,700–2,800 crores at current pricesNo date
CapexINR150–200 crores including growth, infra, automationFY26
Paracetamol capacity consolidationShift old 3,600 MTPA to new 10,800 MTPA plant; eventual capacity 10,800 tonsNo date
Acetic anhydride Europe recertificationUnder process, expected very soonNo date
Greenfield expansionEnvironmental clearance and NHI/Pollution Control Board permissions startedProgressing into FY26

Key Metrics

MetricQ4 FY25
Revenue from operations₹528 cr, 4.7% YoY growth vs ~₹504 cr in Q4 FY24
Full-year FY25 revenue₹2,079 cr
EBITDA~₹67 cr, up 17% YoY from ~₹58 cr in Q4 FY24
EBITDA margin12.7%, improvement of 141 bps YoY
Full-year FY25 EBITDA margin~11%
PAT₹31.6 cr, up 12% YoY from ₹28 cr in Q4 FY24
PAT margin5.9%, increase of 43 bps YoY
Full-year FY25 PAT₹101 cr, PAT margin 4.8%
Cash PAT₹56.4 cr, up ~15% YoY from ₹49.2 cr in Q4 FY24
Full-year FY25 cash PAT₹185 cr
Net debt to equity ratio0.09 at end of FY25
Revenue split (Ibuprofen vs non-Ibuprofen)~65% Ibuprofen, ~35% non-Ibuprofen
Non-Ibu portfolio share of API revenues~34%, up from 18% five years ago
Chemical segment EBITDA margin6%, vs 3% in Q4 FY24
Export revenue share27%, target 40%–45% over medium term
Chemical export revenue share~18% during FY25, up from 10%–12% previously
Peak revenue from existing capacity₹2,700–2,800 cr at current prices
Expected FY26 revenue growth10% to 15%, mix of volume and price
Expected FY26 EBITDA marginmore than 15%
FY26 capex plan₹150–200 cr, same as last 2–3 years
Paracetamol capacity (new plant)10,800 MTPA, old plant of 3,600 MTPA to be phased out
Clopidogrel capacity expansion33% increase
DMFs filed16
CEPs filed19
Land acquired for greenfield expansion101 acres along Chandigarh-Bathinda Highway